Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340571 · ClinicalTrials.gov registry record
Blood Biomarker of Alzheimer's Disease (AD)
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 21
- Enrollment target
NCT03340571 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 21 participants.
The verdict
NCT03340571 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-03-12 |
| Est. Completion | 2019-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03340571
The ClinicalTrials.gov registry entry for NCT03340571 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT03340571 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03340571 about?
NCT03340571 is a clinical study titled "Blood Biomarker of Alzheimer's Disease (AD)". Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure ...
What is the current status of trial NCT03340571?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2018-03-12. Estimated completion is 2019-07-31.
Who is sponsoring clinical trial NCT03340571?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.